Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2025-11-14 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report
Regulatory Filings Classification · 90% confidence The document is a Monitoring Agency Report filed with the stock exchange under SEBI LODR Regulation 32(6) and ICDR Regulations for utilisation of proceeds of a preferential issue. It is not a financial results announcement (IR) nor an earnings release (ER), nor a new capital/financing announcement (CAP). It is a mandatory compliance disclosure under listing regulations and does not contain standalone financial statements. Therefore it falls under general regulatory filings.
2025-11-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a full transcript of a company's earnings conference call for the first half of fiscal year 2026 (H1 FY26). It includes detailed financial performance data such as sales, EBITDA, PAT margins, segmental revenue mix, and growth commentary. The text also contains a Q&A session with analysts discussing financial metrics and business segments. The presence of management commentary, financial figures, and Q&A indicates this is a Call Transcript (CT) rather than a brief earnings release or a formal report. The document length (15,000 characters) and detailed content confirm it is not a short announcement or a report publication notice. Therefore, the appropriate classification is Call Transcript (CT).
2025-11-13 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an official communication from Beta Drugs Limited to the National Stock Exchange of India regarding the receipt of in-principle approval for migration of trading from the SME Platform (EMERGE) to the Main Board. It includes a letter from the NSE granting this in-principle approval. The content is an announcement of a regulatory approval related to the company's listing status, not a financial report, earnings release, or management discussion. The document length is short (3277 characters) and primarily serves as an official notification of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2025-11-13 English
Updates
Audit Report / Information Classification · 95% confidence The document is titled 'Secretarial Compliance Report' for Beta Drugs Limited covering the period from April 1, 2024 to October 31, 2025. It is prepared by a Practising Company Secretary and focuses on compliance with various SEBI regulations, listing obligations, and disclosure requirements. The report details compliance status, observations, and any penalties related to regulatory filings and corporate governance. It does not contain financial statements or detailed financial performance data, nor is it an announcement of voting results or management changes. It is a regulatory compliance report related to secretarial and listing obligations, which fits best under the category of Audit Report / Information (AR) as it is a standalone compliance report examining regulatory adherence and internal controls, not a full annual report or interim financial report. H2 2025
2025-11-12 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement addressed to the National Stock Exchange of India regarding the use of proceeds from a Preferential Issue for the half year ended 30th September 2025. It references Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and confirms no deviation or variation in the use of funds raised. The document includes detailed tables showing allocation and utilization of funds, comments from the Audit Committee, and auditor remarks. The document length is 4087 characters, which is relatively short and primarily serves as a compliance statement rather than a full financial report. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory compliance disclosure about the use of proceeds from a capital raising event. This fits best under Regulatory Filings (RNS), as it is a regulatory announcement and compliance document rather than a full report or financial statement.
2025-11-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter addressed to the National Stock Exchange of India regarding the audio recording of an analysts and investors call about the financial results for the half year ended 30th September 2025. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides a link to the recording of the conference call. The document does not contain actual financial data or detailed financial statements but is an announcement related to the conference call recording. Therefore, it is best classified as a Call Transcript (CT) related filing, specifically an announcement of the call recording. Given the nature of the document as an announcement of the call recording rather than the transcript itself, the closest fitting category is Call Transcript (CT).
2025-11-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.